Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2000 3
2008 1
2009 1
2011 8
2013 5
2014 4
2017 1
2020 1
2021 1
2022 1
2024 4
2025 1
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

28 results

Results by year

Filters applied: . Clear all
Page 1
Evaluation of pembrolizumab plus cisplatin and fluorouracil in radical treatment for patients with T4b esophageal squamous cell carcinoma.
Hokamura N, Fukagawa T, Fukushima R, Kiyokawa T, Horikawa M, Soeda N, Suzuki Y, Kaneshiro S, Abe K, Kodashima S, Yamamoto T, Oshima Y, Ishida T, Sasajima Y, Nomoto A, Shiraishi K, Ito A. Hokamura N, et al. BMC Gastroenterol. 2024 Sep 2;24(1):295. doi: 10.1186/s12876-024-03382-w. BMC Gastroenterol. 2024. PMID: 39223478 Free PMC article.
Pembrolizumab plus cisplatin and fluorouracil as induction chemotherapy followed by definitive chemoradiotherapy for patients with cT4 and/or supraclavicular lymph node metastasis (M1Lym) of esophageal squamous cell carcinoma.
Hokamura N, Fukagawa T, Fukushima R, Kiyokawa T, Horikawa M, Kumata Y, Suzuki Y, Midorikawa H. Hokamura N, et al. Surg Today. 2024 Nov;54(11):1410-1413. doi: 10.1007/s00595-024-02867-1. Epub 2024 May 20. Surg Today. 2024. PMID: 38769180 Free PMC article. Review.
The real-world data of immune-checkpoint inhibitor combination therapy for unresectable or metastatic esophageal cancer: a multi-institutional cohort study.
Sato S, Ssuzuki T, Chinen T, Yamaguchi H, Suzuki Y, Hokamura N, Saze Z, Kono K, Takahashi K, Yano F, Kunisaki C, Kosaka T, Endo I, Ichikawa Y, Miyawaki Y, Sato H, Shimada H. Sato S, et al. Among authors: hokamura n. Int J Clin Oncol. 2024 Jul;29(7):994-1001. doi: 10.1007/s10147-024-02532-0. Epub 2024 Apr 28. Int J Clin Oncol. 2024. PMID: 38679627
Endoscopic submucosal dissection for gastric tube cancer after esophagectomy.
Nonaka S, Oda I, Sato C, Abe S, Suzuki H, Yoshinaga S, Hokamura N, Igaki H, Tachimori Y, Taniguchi H, Kushima R, Saito Y. Nonaka S, et al. Among authors: hokamura n. Gastrointest Endosc. 2014 Feb;79(2):260-70. doi: 10.1016/j.gie.2013.07.059. Epub 2013 Sep 21. Gastrointest Endosc. 2014. PMID: 24060521
Prognostic factors of second-line nivolumab monotherapy for unresectable or metastatic esophageal cancer: a multi-institutional cohort study for 184 cases.
Sato S, Suzuki T, Chinen T, Yamaguchi H, Suzuki Y, Hokamura N, Saze Z, Kono K, Takahashi K, Yano F, Sato T, Kosaka T, Endo I, Ichikawa Y, Miyawaki Y, Sato H, Shimada H. Sato S, et al. Among authors: hokamura n. J Gastroenterol. 2024 Nov;59(11):979-985. doi: 10.1007/s00535-024-02141-8. Epub 2024 Aug 17. J Gastroenterol. 2024. PMID: 39153106
Relationship between cervical esophageal squamous cell carcinoma and human papilloma virus infection and gene mutations.
Fukahori M, Kato K, Taniguchi H, Ohtomo R, Takahashi N, Shoji H, Iwasa S, Honma Y, Takashima A, Hamaguchi T, Yamada Y, Shimada Y, Ito Y, Itami J, Hokamura N, Igaki H, Tachimori Y, Miwa K, Torimura T, Boku N. Fukahori M, et al. Among authors: hokamura n. Mol Clin Oncol. 2021 Feb;14(2):41. doi: 10.3892/mco.2020.2205. Epub 2020 Dec 30. Mol Clin Oncol. 2021. PMID: 33437479 Free PMC article.
28 results